# Solid Biosciences (SLDB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SLDB
## Company Profile
- Ticker: SLDB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 9.065 USD
- Market cap: 647798407.48 USD
- Last updated: 2026-08-12
## Business Overview
### Neuromuscular Gene Therapy Company
Solid Biosciences develops adeno-associated virus gene therapies for neuromuscular and cardiac diseases.
### SGT-003
SGT-003 combines a microdystrophin construct with the POLARIS-101 capsid, designed to improve skeletal and cardiac muscle delivery while reducing liver targeting in Duchenne muscular dystrophy.
### Cardiac Gene Therapy Pipeline
Additional programs include SGT-212 for Friedreich’s ataxia and SGT-501 for catecholaminergic polymorphic ventricular tachycardia.
## Why The Stock Is Moving

As of Aug 12, 2026, SLDB closed up 2.43% at $9.06. No new same-company headline was identified in the current news window.

## Future Catalysts

- Solid expects to dose the first participant in the Phase 1b ARTEMIS study of SGT-501 in the second half of 2026.
- The Phase 3 IMPACT DUCHENNE study of SGT-003 is underway, with future enrollment and data supporting the global registration program.

## Recent News
- 2026-08-06 20:08 EST — [Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-second-quarter-2026-financial-results-and-provides-bus-f3dbe474) — Source: Solid Biosciences
- 2026-06-01 20:05 EST — [Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-8b813e20) — Source: Solid Biosciences
- 2026-06-01 12:00 EST — [Solid Biosciences to Participate at Upcoming Investor Conferences](https://biopharmsignal.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-2a3e1bc2) — Source: Solid Biosciences
- 2026-05-12 20:08 EST — [Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-first-quarter-2026-financial-results-and-provides-busi-5df78103) — Source: Solid Biosciences
- 2026-05-07 12:00 EST — [Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/SLDB/solid-biosciences-doses-first-participant-in-phase-3-impact-duchenne-clinical-tr-0b3eb7cf) — Source: Solid Biosciences